Business Description
PharmaEssentia Corp
ISIN : TW0006446008
Compare
Compare
Traded in other countries / regions
6446.TaiwanPHECR.Luxembourg IPO Date
2014-03-11Description
PharmaEssentia Corp is engaged in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug pattern developments. It focuses on Hematology, Oncology, and Infectious Disease. The company derives its revenue from sales of medicine products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.4 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | 0.44 | |||||
| Interest Coverage | 46.32 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 38.96 | |||||
| Beneish M-Score | -1.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 91 | |||||
| 3-Year EBITDA Growth Rate | 33.9 | |||||
| 3-Year EPS without NRI Growth Rate | 37.6 | |||||
| 3-Year FCF Growth Rate | 2.4 | |||||
| 3-Year Book Growth Rate | 69.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.25 | |||||
| 9-Day RSI | 46.02 | |||||
| 14-Day RSI | 44.59 | |||||
| 3-1 Month Momentum % | -8.77 | |||||
| 6-1 Month Momentum % | 28.93 | |||||
| 12-1 Month Momentum % | 84.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.31 | |||||
| Quick Ratio | 11.67 | |||||
| Cash Ratio | 10.39 | |||||
| Days Inventory | 475.31 | |||||
| Days Sales Outstanding | 75.94 | |||||
| Days Payable | 45.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 | |||||
| Shareholder Yield % | 0.21 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.1 | |||||
| Operating Margin % | 12.77 | |||||
| Net Margin % | 22.19 | |||||
| FCF Margin % | 5.01 | |||||
| ROE % | 7.47 | |||||
| ROA % | 6.65 | |||||
| ROIC % | 15.56 | |||||
| 3-Year ROIIC % | 11.58 | |||||
| ROC (Joel Greenblatt) % | 43.81 | |||||
| ROCE % | 7.58 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 105.53 | |||||
| Forward PE Ratio | 37.82 | |||||
| PE Ratio without NRI | 105.53 | |||||
| Price-to-Owner-Earnings | 194.03 | |||||
| PEG Ratio | 22.94 | |||||
| PS Ratio | 23.45 | |||||
| PB Ratio | 7.54 | |||||
| Price-to-Tangible-Book | 7.49 | |||||
| Price-to-Free-Cash-Flow | 448.82 | |||||
| Price-to-Operating-Cash-Flow | 125.69 | |||||
| EV-to-EBIT | 86.06 | |||||
| EV-to-EBITDA | 72.17 | |||||
| EV-to-Revenue | 20.18 | |||||
| EV-to-FCF | 410.76 | |||||
| Price-to-GF-Value | 0.58 | |||||
| Price-to-Projected-FCF | 451.16 | |||||
| Price-to-Graham-Number | 5.88 | |||||
| Price-to-Net-Current-Asset-Value | 8.94 | |||||
| Price-to-Net-Cash | 10.87 | |||||
| Earnings Yield (Greenblatt) % | 1.16 | |||||
| FCF Yield % | 0.22 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers